Patients with advanced melanoma receiving tumor-infiltrating lymphocyte (TIL) therapy appear to fare much better after hospital discharge than previously assumed. A retrospective study from Memorial Sloan Kettering Cancer Center tracked 51 patients treated with investigational LN-144 or the FDA-approved lifileucel (Amtagvi) between 2020 and 2024, finding that serious treatment-related complications post-discharge were uncommon — offering reassurance to both patients and care teams.

The findings suggest that current post-discharge monitoring protocols — largely modeled after CAR-T therapy, which carries risks like cytokine release syndrome weeks after infusion — may be more intensive than necessary for TIL patients. Clinicians may have room to tailor follow-up plans to individual patient needs, including those who travel long distances for treatment.

By the Numbers:

• Only 4% (2 of 51) developed a new grade 3 or 4 treatment-related adverse event after discharge
• 4 patients were readmitted due to treatment-related toxicities; 7 were readmitted for disease progression
• ~24% (12 patients) needed at least one blood product transfusion post-discharge
• Lifileucel's overall response rate in melanoma is approximately 30%

Why it matters: These data give oncology teams a stronger evidence base to move away from one-size-fits-all CAR-T-style monitoring and toward more flexible, patient-centered follow-up care for TIL therapy — potentially improving quality of life without compromising safety.